Italy vs Slovenia: Death rate from cancer
Italy
296.07 deaths per 100,000 people
in 2021
Slovenia
305.17 deaths per 100,000 people
in 2021
Italy rank
10th
Slovenia rank
8th
Death rate from cancer over time
- Italy
- Slovenia
How they compare
Slovenia currently reports 305.17 deaths per 100,000 people against 296.07 deaths per 100,000 people in Italy, a difference of 9.1 deaths per 100,000 people.
The two have swapped places 3 times across 22 shared years of data; in 2000 it was Italy ahead.
Italy ranks 10th and Slovenia ranks 8th of 194 countries.
Across the 3 decades both report, Italy averaged higher in 1 and Slovenia in 2.
Head to head by decade
| Decade | Italy | Slovenia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 280.32 deaths per 100,000 people | 263.52 deaths per 100,000 people | 16.8 deaths per 100,000 people | Italy |
| 2010s | 287.86 deaths per 100,000 people | 297.12 deaths per 100,000 people | 9.26 deaths per 100,000 people | Slovenia |
| 2020s | 293.43 deaths per 100,000 people | 306.26 deaths per 100,000 people | 12.83 deaths per 100,000 people | Slovenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Italy or Slovenia?
- Slovenia, at 305.17 deaths per 100,000 people against 296.07 deaths per 100,000 people in Italy as of 2021.
- What is the difference in death rate from cancer between Italy and Slovenia?
- 9.1 deaths per 100,000 people, with Slovenia ahead.
- How many years of comparable data are there for Italy and Slovenia?
- 22 years are reported by both, from 2000 to 2021.
- How do Italy and Slovenia rank globally for death rate from cancer?
- Italy ranks 10th and Slovenia ranks 8th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.